Goldman Sachs Maintains Buy on NeoGenomics, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a 'Buy' rating on NeoGenomics (NASDAQ:NEO) but lowered the price target from $19 to $17.
October 20, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on NeoGenomics but lowered the price target from $19 to $17.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term value of the stock. However, the impact may be neutral as the 'Buy' rating is still in place.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100